What does this research mean for the field?

R-CHOP therapy achieves high response rates and favorable long-term survival in breast-involved diffuse large B-cell lymphoma, and high-dose methotrexate prophylaxis may effectively prevent central nervous system relapses in this population. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate clinical characteristics, long-term survival outcomes, and central nervous system (CNS) relapse patterns in patients with newly diagnosed breast-involved diffuse large B-cell lymphoma (DLBCL).

August 22, 2026Current OncologyOpen Access

Clinical Outcomes of Breast-Involved Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Real-World Study with Insights into CNS Prophylaxis

View Full Paper

Ask AI

Bookmark

Authors

TNThi Thu Huong NguyenVinmec International Hospital TLThi Yen LeNational Economics University TTTung Nguyen ThanhHanoi Medical University

Discussion

Member takes

Implication

Retrospective study reveals reduced central nervous system relapse with high-dose methotrexate in breast-involved lymphoma, indicating the potential benefit of targeted prophylaxis.

Key Points

To evaluate clinical characteristics, long-term survival outcomes, and central nervous system (CNS) relapse patterns in patients with newly diagnosed breast-involved diffuse large B-cell lymphoma (DLBCL).
Retrospective analysis of N=33 consecutive patients with newly diagnosed breast-involved DLBCL treated with R-CHOP between 2019 and 2024.
Patients underwent baseline CNS screening (neurological examination, fundoscopy, brain MRI, and CSF analysis), and high-dose methotrexate (HD-MTX) was offered as post-therapy CNS prophylaxis based on multidisciplinary evaluation.
The overall response rate was 90.9% with an 84.8% complete response rate; at a median follow-up of 44 months, 5-year overall survival was 84.8% and progression-free survival was 66.7%.
CNS relapse occurred in 4 of 6 patients (66.7%) without prophylaxis (within 5–11 months post-R-CHOP) compared to 0 of 27 patients receiving HD-MTX prophylaxis (p < 0.001).
Exploratory analyses indicated that bulky disease was associated with inferior overall survival.

Cite This Study

Nguyen et al. (2026) studied this question.

synapsesocial.com/papers/6a895fd3ca7ade938187eaee https://doi.org/10.3390/curroncol33080493

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study reveals reduced central nervous system relapse with high-dose methotrexate in breast-involved lymphoma, indicating the potential benefit of targeted prophylaxis.

Clinical Outcomes of Breast-Involved Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Real-World Study with Insights into CNS Prophylaxis

Discussion

Member takes

Implication

Key Points

Cite This Study

Clinical Outcomes of Breast-Involved Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Real-World Study with Insights into CNS Prophylaxis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider